Funding Opportunity RFA-AG-22-016 from the NIH Guide for Grants and Contracts. The ultimate goal of this R61/R33 Funding Opportunity Announcement (FOA) is to identify meaningful (e.g., causal), modifiable factors that promote adherence to lifestyle changes or to other (e.g., cognitive training) behaviors that hold potential for prevention of cognitive decline, MCI, and AD/ADRD. Specifically, this will be done by conducting research to understand how, why, and for whom particular features of behavior change interventions engage specific psychological or interpersonal processes that promote maintenance of (adherence to) health behaviors. Applications in response to this FOA (and to the companion R01 FOA) should be framed within the NIH Stage Model. Additionally, this FOA supports new early- to late- stage (including Stages I-IV) research projects. Projects should create, refine, and test interventions that target individual- and interpersonal-level mechanisms of adherence to healthful behavioral patterns and to other prevention approaches for cognitive decline, MCI, and AD/ADRD (e.g., cognitive training). Additionally, this FOA supports studies that integrate basic science questions of how psychological and interpersonal targets (i.e., processes we can manipulate) and mechanisms may inform the design and development of effective, efficient, and personalized approaches to promote adherence to behavior change for the prevention of AD/ADRD and to help optimize healthy aging over the life course.

Funding Opportunity RFA-HD-21-033 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support interdisciplinary community-engaged research designed to reduce or eliminate infections and sepsis as causes of pregnancy-related or associated morbidity and mortality (PRAMM) in regions of the United States with high rates of maternal mortality. This FOA is to support research primarily focused on PRAMM health disparities in areas with highest maternal morbidity and mortality.

Notice NOT-OD-21-087 from the NIH Guide for Grants and Contracts

New study highlights a pitfall of overly specialized language

Dependant on Experience plus benefits: DefiniGEN: We have an exciting opportunity for a full-time Bioinformatician/Genome Analyst to join DefiniGEN a world-leading... Babraham Research Campus, Cambridge, UK

Collaborate with the Clinical Development Operations, Biometrics, and Bioinformatics functions to manage the timely testing of clinical trial samples and the…
From Seagen - Tue, 06 Apr 2021 06:13:51 GMT - View all Bothell, WA jobs

Funding Opportunity RFA-RM-21-020 from the NIH Guide for Grants and Contracts. The purpose of this specific FOA is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the KMC as well as the broader IDG Consortium in the following ways: (1) by developing and deploying tools to enhance the community's ability to process, analyze, and visualize IDG data, (2) to prioritize new data resources and methods to be incorporated into Pharos https://pharos.nih.gov/idg/index that will strengthen predictions about physiological and disease associations around the understudied proteins, and (3) by developing methods to prioritize understudied IDG families (non-olfactory GPCRs, protein kinases, and ion channels) for deeper study using experimental assays both within the IDG pipeline or by the larger community.

Funding Opportunity PAR-21-188 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences

Funding Opportunity RFA-DK-21-501 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites one application from the Program Director/Principal Investigator (PD/PI) of the current Data Coordinating Center (DCC) for Type 1 Diabetes Acute Pancreatitis Consortium (T1DAPC). This 5-year longitudinal observational clinical study was originally funded in September 2020 and is currently in its planning phase. It will conduct a prospective longitudinal observational study of the occurrence of new onset diabetes during an acute pancreatitis (AP) episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study is designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes after AP. The DCC is involved in coordination and study design, including data and biosample acquisition and management and is responsible for distribution of funding to the clinical centers for participant costs. This supplement provides funding for the T1DAPC DCC to support longitudinal Magnetic Resonance Imaging (MRI) and other types of biomarker studies of enrolled participants.

Notice NOT-LM-21-006 from the NIH Guide for Grants and Contracts

Notice NOT-AA-21-012 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-053 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-021 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-054 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-091 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-089 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-21-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of the NCI, Division of Cancer Treatment and Diagnosis (DCTD), Office of Cancer Clinical Proteomics Research (OCCPR), Clinical Proteomic Tumor Analysis Consortium (CPTAC) program. This reissuance of the CPTAC program leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating research resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science.

Funding Opportunity RFA-CA-21-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science.

Funding Opportunity RFA-CA-21-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by theOffice of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating research resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images, and reagents) that catalyze hypothesis-driven science.

Competitive Salary: EMBL: About this position We are seeking to recruit an experienced and enthusiastic Purchasing Assistant to work in our small Purchasing team at the Euro Hinxton, Cambridgeshire, England